Agreement Term; Expiration. This Agreement is effective as of the Effective Date and, unless earlier terminated pursuant to the other provisions of this ARTICLE 10, will continue in full force and effect until this Agreement expires as follows: 10.1.1. on a country-by-country basis, on the date of expiration of all payment obligations by the Commercializing Party under this Agreement with respect to the Product (or a Discontinued Product) in such country; 10.1.2. in its entirety upon the expiration of all payment obligations under this Agreement with respect to the Product (or a Discontinued Product) in all countries pursuant to Section 10.1.1; and 10.1.3. where Biogen Idec has not provided Isis a written notice stating Biogen Idec is exercising its Option and paid Isis the license fee under Section 6.3 by the Option Deadline. The period from the Effective Date until the date of expiration of this Agreement pursuant to this Section 10.1 is the “Agreement Term.”
Appears in 2 contracts
Samples: DMPK Research, Development, Option and License Agreement (Isis Pharmaceuticals Inc), Development, Option and License Agreement (Isis Pharmaceuticals Inc)
Agreement Term; Expiration. This Agreement is effective as of the Effective Date and, unless earlier terminated pursuant to the other provisions of this ARTICLE 10, will continue in full force and effect until this Agreement expires as follows:
10.1.1. on a country-by-country basis, on the date of expiration of all payment obligations by the Commercializing Party under this Agreement with respect to the Product all Products (or a Discontinued ProductProduct(s)) in such country;
10.1.2. in its entirety upon the expiration of all payment obligations under this Agreement with respect to the Product all Products (or a Discontinued ProductProducts) in all countries pursuant to Section 10.1.1; and
10.1.3. where every Option has expired as a result of Biogen Idec has not provided providing Isis a written notice stating Biogen Idec is exercising its Option such Options and paid paying Isis the applicable license fee fees under Section 6.3 by the Option Deadline, or as a result of Section 1.5.2(d) or Section 10.4.2. The period from the Effective Date until the date of expiration of this Agreement pursuant to this Section 10.1 is the “Agreement Term.”
Appears in 1 contract
Agreement Term; Expiration. This Agreement is effective as of the Effective Date and, unless earlier terminated pursuant to the other provisions of this ARTICLE 10, will continue in full force and effect until this Agreement expires as follows:
10.1.1. on a country-by-country basis, on the date of expiration of all payment obligations by the Commercializing Party under this Agreement with respect to the Product all Products (or a Discontinued ProductProduct(s)) in such country;
10.1.2. in its entirety upon the expiration of all payment obligations under this Agreement with respect to the Product all Products (or a Discontinued ProductProducts) in all countries pursuant to Section 10.1.1; and
10.1.3. where every Option has expired as a result of Biogen Idec has not provided Isis providing Ionis a written notice stating Biogen Idec is exercising its Option such Options and paid Isis paying Ionis the applicable license fee fees under Section 6.3 by the Option Deadline, or as a result of Section 1.5.2(d) or Section 10.4.2. The period from the Effective Date until the date of expiration of this Agreement pursuant to this Section 10.1 is the “Agreement Term.”
Appears in 1 contract
Agreement Term; Expiration. This Agreement is effective as of the Effective Date and, unless earlier terminated pursuant to the other provisions of this ARTICLE 10, will continue in full force and effect until this Agreement expires as follows:
10.1.1. on a country-by-country basis, on the date of expiration of all payment obligations by the Commercializing Party under this Agreement with respect to the Product all Products (or a Discontinued ProductProducts) in such country;
10.1.2. in its entirety upon the expiration of all payment obligations under this Agreement with respect to the Product all Products (or a Discontinued ProductProducts) in all countries pursuant to Section 10.1.1; and;
10.1.3. where no Development Candidates have been designated by the expiration of the ASO Development Candidate Identification Term as described in Section 1.9; and
10.1.4. where every Option has expired as a result of Biogen Idec has not provided Isis providing Ionis a written notice stating Biogen Idec is exercising its Option such Options and paid Isis paying Ionis the applicable license fee fees under Section 6.3 6.2 by the Option Deadline. The period from the Effective Date until the date of expiration of this Agreement pursuant to this Section 10.1 is the “Agreement Term.”
Appears in 1 contract
Samples: Research Collaboration, Option and License Agreement (Ionis Pharmaceuticals Inc)